http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
저가 다결정 EFG 리본 웨이퍼의 표면 반사도 특성 최적화
김병국,이용구,저호,오병진,박재환,이진석,장보윤,안영수,임동건,Kim, Byeong-Guk,Lee, Yong-Koo,Chu, Hao,Oh, Byoung-Jin,Park, Jae-Hwan,Lee, Jin-Seok,Jang, Bo-Yun,An, Young-Soo,Lim, Dong-Gun 한국전기전자재료학회 2011 전기전자재료학회논문지 Vol.24 No.2
Ribbon silicon solar cells have been investigated because they can be produced with a lower material cost. However, it is very difficult to get good texturing with a conventional acid solution. To achieve high efficiency should be minimized for the reflectance properties. In this paper, acid vapor texturing and anti-reflection coating of $SiN_x$ was applied for EFG Ribbon Si Wafer. P-type ribbon silicon wafer had a thickness of 200 ${\mu}m$ and a resistivity of 3 $\Omega-cm$. Ribbon silicon wafers were exposed in an acid vapor. Acid vapor texturing was made by reaction between the silicon and the mixed solution of HF : $HNO_3$. After acid vapor texturing process, nanostructure of less than size of 1 ${\mu}m$ was formed and surface reflectance of 6.44% was achieved. Reflectance was decreased to 2.37% with anti-reflection coating of $SiN_x$.
비호지킨 림프종에 대한 CHOP 및 CHOP / IMVP - 16 복합화학요법의 치료 효과
강원기(Won Ki Kang),윤성수(Sung Soo Yoon),신동복(Dong Bok Shin),강윤구(Yoon Koo Kang),박근칠(Keun Chil Park),방영주(Yung Jue Bang),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.3
N/A The authors compared retrospectively two regimens, CHOP and CHOP/IMVP-16 for the patients with intermediate and high grade non-Hodgkin's lymphoma. Between September 1982 and May 1984, 48 patients were treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP), and between June 1984 and November 1986, 70 patients were treated with alternating chemotherapy with CHOP and ifosfamide, methotrexate, and VP-16 (CHOP/IMVP-16). Median age was 42 (range 20-64) in CHOP group and 50 (range 16-74) in CHOP/IMVP-16 group and M:F ratio was 42:6 and 50:20 in each group respectively. No patients had received any previous cytotoxic chemotherapy. The most common histologic types were diffuse histiocytic (DH) and diffuse poorly differentiated lymphocytic (DPDL) with DH 36/48 (75%) and DPDL 6/48 (12.4%) in CHOP group, and DH 50/70 (71.4%) and DPDL 15/70 (21.4%) in CHOP/IMVP-16 group. CHOP consisted of cyclophosphamide 1 g/㎡ 4, day 1; adriamycin 40 ㎎/㎡ 4, day 1; vincristine 2 ㎎/m 4, day 1&8; and predrisone 60 ㎎ PO, day 1-10. And IMVP-16 consisted of ifosfamide 1 g/㎡ 4, day 1-5; methotrexate 30 ㎎/㎡ 4, day 3&10; and VP-16 100 ㎎/㎡ 4, day 1-3. Courses were repeated every 3 weeks. In CHOP/IMVP-16 group, CHOP and IMVP-16 were given alternatingly. Treatment was continued until the disease progression or complete remission (CR), for a total of minimum of 6 cycles. Responses were CR 25/48 (52%) and PR 17/48 (35%) in CHOP group and CR 38/70 (54%) and PR 22/70 (31%) in CHOP/IMVP-16 group. Median duration of response in complete responders was 17.7 months (range 3.0-77+) in CHOP, and 18.4 months (range 2.2+~48.3+) in CHOP/IMVP-16 group. And, in complete responders, 3-year disease-free survival rate is 32.5% and 39.2% in CHOP group and CHOP/IMVP-16 group respectively. Median survival time was 17.5 months (range 3.4~80.4+) in CHOP group and 22.7 months (range 1~51+) in CHOP/IMVP-16 group. There was no statistically significant difference between CHOP and CHOP/IMVP-16 groups.
임영혁(Young Hyuk Im),이제환(Je Hwan Lee),정경해(Kyung Hae Jung),강윤구(Yoon Koo Kang),박근칠(Keun Chil Park),신동복(Dong Bok Shin),이재훈(Jae Hoon Lee),허대석(Dae Seog Heo),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe K 대한내과학회 1990 대한내과학회지 Vol.39 No.4
N/A Twenty-one previously untreated patients with acute lymnocytic leukemia were treated with induction chemotherapy consisting of vincristine, prednisolone, daunorubicin, and L-asparaginase. After sucessful remission induction, CNS prophylaxis was performed with cranial irradiation and intrathecal methotrexate, and alternating chemotherapy with non-cross-resistnat agents was used in consolidation therapy. The results were as follows; 1) Fifteen out of 18 (83.3%) cases achieved complete remission, and the median duration of remission was 26.8 weeks (4-111+weeks). 2) The overall median survival of the patients was 24.8 weeks (2-120+ weeks). 3) The median survival of the responders was longer than that of the nonresponders (38 weeks vs four weeks). 4) The only favorable factor influencing the remission rate was age below 20 years (p<0.05), and the favorable prognostic factor for remission duration was time to remission (<four weeks). 5) Sevent out of 15 (47%) patients in remission suffered relapse, and the sites of relapse were the bone marrow and central nervous system. 6) Non-hematologic toxicities during induction chemotherapy were hepatotoxicity (such as jaundice, elevation of hepatic enzymes, and glucose intolerance), mainly due to L-asparaginase: hematologic toxicities were tolerable. In conclusion, this induction regimen was useful in terms of remission rate, however, it was thought to be ineffective because of the considerable number of side effects and the shortness of the remission duration.
이근석(Keun Seok Lee),이윤종(Yun Jong Lee),이원섭(Won Sup Lee),안진석(Jin Seok Ahn),이종태(Jong Tae Lee),김원석(Wen Seong Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),박선양(Seon Yang Park),조광현(kwang Hyun Cho),김병국(Byoung Koo 대한내과학회 1996 대한내과학회지 Vol.51 No.3
Objectives: Sweet`s syndrome(acute febrile neutrophilic dermetosis) is characterized by fever, neutrophilia, erythematous painful cutaneous plaques, a dense dermal infiltrate onsisting of mature neutrophils, and a rapid response to steroid therapy, This condition is clinically important because it is associated with malignancy and it should be one of the differential diagnosis in the febrile immunocompromized patients with skin lesion, In spite of its clinical importance, there was no report on the epidemiologic characteristics of Sweets syndrome in Korean patients so far because of the rarity of Sweet`s syndrome, This study was performed to investigate characteristics and clinical significance of Sweet`s syndrome in Korean patients. Methods : The authors report a case of Sweet`s syndrome associated with acute myelogenous leukemia, and review the other 23 Korean patients with Sweet's syndrome that have been published in the literature. The characteristics of malignancy-associa- ted Sweet`s syndrome are compared with those of Sweet`s syndrome without malignancy association. Results: 1) Twenty-four cases of Sweet`s syndrome were analysed. Male to female ratio was 8:16 and the mean age was 44.8± 11.7 years. In 79% of patients, fever was noticed during the episodes of Sweet's syndrome. The most frequent sites of skin lesions were the upper extremities(83%), followed by face and head(75%), the lower extremities(75%), neck(46%), and trunk (13%). 2) Associated underlying systemic disorders were present in 15(62%) of the patients. The most frequent associations were chronic inflammatory bowel disease in seven patients, hematologic neoplasia in five, and solid neoplasia in one patients. 3) Leukocyte counts(mean 13,400±8,000/mm3) were higher than 10,000/mm3 in 16(67%) of patients. Erythrocyte sedimentation rates(mean 66.8±44.4mm/ hour) were elevated in 18(82%) of patients. 4) Skin lesion improvements were observed within 2 to 5 days from the initiation of steroid therapy. 5) Malignancies were associated in 6 patients. The initial appearance of Sweet`s syndrome lesions preceded or occurred concurrently with the detection of previously unsuspected malignancy in 67%(4 of 6 patients), In malignancy associated Sweet's syndrome, relative male preponderance, older age, and higher leukocyte counts were observed compared with Sweet's syndrome which is not associated with malignancy. There were no statistical significances, however. The erythrocyte sedimentation rate was the only statistically significant parameter. Conclusion: The characteristics of Sweet`s syndrome in Korean patients were similar to the characteristics of their western counterparts. Workup for malignancy seems appropriate far newly diagnosed Sweet`s syndrome patients in case of elevated erythrocyte sedimentation rate, leukocytosis, old age, and male sex
조광현,이광우,김철우,김노경,지제근,최성재,강윤구,방영주,김병국,주승재 대한내과학회 1987 대한내과학회지 Vol.33 No.4
POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M-component, and Skin changes) syndrome, also called as Takatsuki syndrome or Crow-Fukase syndrome, is a multisystemic syndrome that encompasses progressive peripheral neuropathy, papilledema, increased CSF protein, hepatomegaly, splenomegaly, lymphadenopathy, diabetes mellitus, gynecomastia and impotence, amenorrhea, hypothyroidism, osteosclerotic bone lesion, plasma cell dyscrasia, and thickening, hyperpigmentation and hypertrichosis of the skin. Recently, we experienced a 39-year-old male who had been suffered from generalized weakness, both shoulder pain, leg pain, weakness of the lower extremities, impotence, hoarseness, dysphagia, and aspiration of food. He had various signs such as peripheral neuropathy, papilledema, hepatomegaly, splenomegaly, primary gonadal failure, hyperprolactinemia, hypothyroidism, hypoparathyroidism, osteosclerotic bone lesions, and plasmacytoma by bone biopsy, erythematous papules of the skin proven to be proliferating endotheliosis by biopsy, leg edema, ascites and pericardial effusion. He also had hyperkalemia, decreased fractional excretion of potassium and hyporeninemic hypoaldosteronism.